Differential expression of galectin 3 and galectin 1 in colorectal cancer progression

Sanjuán, Xavier; Fernandez, P. L.; Castells, Antoni; Castronovo, Vincenzo; Brûle, Frédéric van den; Liu, F. T.; Cardesa, Antonio; Campo, Elı́as

doi:10.1016/s0016-5085(97)70010-6

Cited by 185 publications

(155 citation statements)

References 4 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Our experimental results based on the LNCaP prostate cancer cell line are in perfect agreement with our previous observations that cancer cells of primary tumors from endometrium, colon and prostate are characterized by progression patterns depending on Gal-3 localization (van den Bruˆle et al, 1996Bruˆle et al, , 2000Sanjuan et al, 1997). However, primary tumors are heterogeneous, and emergence of a subset of more aggressive cancer cells provides an explanation for tumor progression (Hanahan and Weinberg, 2000).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

et al. 2004

View full text Add to dashboard Cite

Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Sanjuan et al (1997) demonstrated downregulation of Gal-3 expression in colorectal cancer, with increased cytoplasmic expression of Gal-3 at more advanced stages. Lotz et al (1993) reported that exclusion of the lectin from the nucleus correlates with transition from normal mucosa to adenoma and carcinoma.…”

Section: Introductionmentioning

confidence: 88%

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The results were judged double-blindly by 2 pathologists. The level of galectin-3 expression was classified into negative (-), weakly positive (+), positive (++) and strong positive (+++) as previously described [7] .…”

Section: Immunohistochemistry Analysismentioning

confidence: 99%

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Liu

Huang²,

Yang³

et al. 2008

WJG

View full text Add to dashboard Cite

and MCP treatment groups was significantly higher than that in the negative control group. However, there was no significant difference between them. Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference. CONCLUSION: Expression of galectin-3 increases significantly in liver metastasis of colon cancer, which can be effectively inhibited by MCP.

show abstract

“…Gal-1 is a multifunctional protein involved in various aspects of tumorigenesis (cell-extracellular matrix and cell-cell interactions, cell migration, angiogenesis, tumor-immune escape) and has been described as a promising cancer target (11)(12)(13). Gal-1 expression has been examined in several malignant tumors (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24), and its correlation with tumor invasiveness and lymph node metastasis was demonstrated in breast cancer (25), neuroblastoma (26), oral squamous cell carcinoma and lung adenocarcinoma (27). Although Kondoh et al (28) showed that the activation of LGALS1 gene expression in HCC results from promoter hypomethylation, data on Gal-1 protein expression in HCC and its correlation to clinicopathological parameters were not available.…”

Section: Introductionmentioning

confidence: 99%

Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness

Spano

Russo

Maso

et al. 2009

Mol Med

View full text Add to dashboard Cite

Hepatocellular carcinoma is one of the most common cancers worldwide. Despite several efforts to elucidate hepatocellular carcinoma molecular pathogenesis, it is still not fully understood. To acquire further insights into the molecular mechanisms of hepatocellular carcinoma, we performed a systematic functional genomic approach on human HuH-7 and JHH-6 cells. The subsequent analysis of the differentially expressed genes in human specimens revealed a molecular signature of 11 genes from which we selected the LGALS1 gene, which was overexpressed in hepatocellular carcinoma. The expression analysis in humans of Galectin-1 (Gal-1), the protein encoded by LGALS1, showed a Gal-1 preferential accumulation in the stromal tissue around hepatocellular carcinoma tumors. Moreover, a significant association between increased expression of Gal-1 in hepatocellular carcinoma and the presence of metastasis was observed. Interestingly, Gal-1 overexpression resulted in an increase of cell migration and invasion. In conclusion, this study provides a portfolio of targets useful for future investigations into molecular marker-discovery studies on a large number of patients and functional assays. In addition, our data provide evidence that Gal-1 plays a role in hepatocellular carcinoma cell migration and invasion, and we suggest that further studies should be conducted to fully establish the role of Gal-1 in hepatocellular carcinoma pathogenesis and evaluate Gal-1 as a potential molecular therapeutic target.

show abstract

Differential expression of galectin 3 and galectin 1 in colorectal cancer progression

Cited by 185 publications

References 4 publications

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness

Contact Info

Product

Resources

About